Document:

Exhibit 4.1

 

NEITHER
THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR ANY APPLICABLE STATE SECURITIES LAW, AND NO INTEREST HEREIN OR THEREIN MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED
OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES
LAWS COVERING ANY SUCH TRANSACTION, (B) THE COMPANY RECEIVES AN OPINION OF COUNSEL FOR THE HOLDER OF SUCH SECURITIES (CONCURRED
IN BY COUNSEL FOR THE COMPANY) THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION, OR (C) THE COMPANY OTHERWISE SATISFIES ITSELF
THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION.

 

THERALINK
TECHNOLOGIES, INC.

 

2021
CONVERTIBLE SECURED PROMISSORY NOTE

 

	$1,000,000.00	 

        

        Golden,
        Colorado

        

        Issue
        Date: MAY 12, 2021

 

FOR
VALUE RECEIVED, Theralink Technologies, Inc., a Nevada corporation (the “Company”), promises to pay
to the order of Ashton Capital Corporation (the “Holder”) the principal amount of $1,000,000 (the “Principal
Amount”) upon the terms and subject to the conditions set forth herein (this “Note”).
This Note is issued pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) between the
Company and Holder and is one of a series of promissory notes to be issued by the Company known as the 2021 Convertible Secured
Promissory Notes (collectively referred to as the “2021 Notes”), all of which contain substantially
similar terms. The 2021 Notes are intended to provide financing to the Company in anticipation of a listing on a Qualified National
Exchange (as defined below).

 

1.       Interest.
Interest shall accrue on the outstanding Principal Amount, from the Issue Date until the date this Note is converted or paid in
full, at the rate of eight percent (8.0%) per annum simple interest (365 day basis) (the “Interest Rate”).
The Company will pay interest quarterly, in arrears, in cash, on the first day of each quarter of each year following the Issue
Date prior to the maturity of this Note, or if any such day is not a Trading Day, on the next succeeding Trading Day (each, an
“Interest Payment Date”). Notwithstanding the immediately foregoing, at the option of the holder, interest
may accrue on this Note on a quarterly basis. All accrued and unpaid interest shall be due and payable in full upon maturity,
conversion or prepayment of this Note, as provided herein. All cash payments received by the Holder in respect of this Note shall
be applied first to accrued interest and thereafter to the repayment of the outstanding Principal Amount.

 

2.       Maturity
Date. If not sooner paid or converted according to the terms hereof, then on May 12, 2026, the Holder may demand the outstanding
Principal Amount plus all accrued and unpaid interest thereon be due and payable (the “Maturity Date”).
Upon the Maturity Date, in lieu of payment, the Holder or the Company may, upon notice to the other party, elect to convert the
outstanding Principal Amount plus accrued and unpaid interest under this Note into a number of shares of the Company’s common
stock (the “Common Stock”) equal to the quotient obtained by dividing:

 

(a)       the
outstanding Principal Amount plus any accrued and unpaid interest under this Note (the “Conversion Amount”),
by

 

(b)       a
per share price of $0.00313 (subject to certain adjustments as set forth herein) (the “Conversion Price”).

 

    	-1-

    	 

    

 

3.       Prepayment. The Notes may be prepaid at any time at an amount equal to 110%
of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Issue Date until the
Maturity Date. In order to prepay the Notes, the Company shall provide five (5) Trading Days prior written notice to the
Holder, during which time the Holder may convert the Notes in whole or in part at the Conversion Price.

 

4.       Covenants.
The Company covenants and agrees that, until all of the obligations under this Note, the Purchase Agreement and the Security
Agreement (as defined below) have been fully performed and either paid in full in cash or converted into shares of Common Stock
of the Company pursuant to the terms hereof and this Note has been terminated, it will abide by the covenants set forth in the
Purchase Agreement and the Security Agreement.

 

5.       Automatic
Conversion. Upon the listing by the Company or the trading of the Common Stock on The Nasdaq Capital Market, The Nasdaq Global Select
Market, The Nasdaq Global Market, the New York Stock Exchange, the NYSE American, the NYSE Arca or any of their respective successor
entities (each a “Qualified National Exchange”), the Conversion Amount shall automatically be converted into
fully-paid and non-assessable shares of Common Stock. The number of shares of Company Stock to be issued upon the conversion contemplated
by this Section 5 shall be equal to the quotient obtained by dividing (i) the Conversion Amount by (ii) the lower of (a) the Conversion
Price (as adjusted as set forth herein); and (b) the average closing price of the Common Stock during the thirty (30) Trading
Days immediately preceding the date of the listing or trading of the Common Stock on a Qualified National Exchange.

 

6.       Optional
Conversion. Subject in all respects to Section 15 of this Note, from and after the Issue Date, the Conversion Amount,
in whole or in part at any time and from time to time may be converted into shares of Company Stock at the election of the Holder,
in its sole discretion. The number of shares of Company Stock to be issued upon the optional conversion of Holder contemplated
by this Section 6 shall be equal to the quotient obtained by dividing (i) the Conversion Amount by (ii) the Conversion
Price. The Holder shall effect conversions by delivering to the Borrower a completed notice in the form attached hereto as Exhibit
A (a “Notice of Conversion”). The date on which a Notice of Conversion is delivered is the “Conversion
Date.” The Borrower shall deliver the applicable stock certificate to the Holder on or before the tenth (10th)
day after a Conversion Date. The Holder shall physically surrender this Note to the Borrower in connection with a conversion,
whether a partial conversion or a total conversion. In the event of a partial conversion, in order to reflect the reduction in
the outstanding principal amount of this Note and the reduction in the accrued and unpaid interest, the Borrower shall prepare
and deliver to the Holder a new Note, identical in all respects to the surrendered Note except for the principal amount outstanding
reflected on the first page hereof and the new Note shall have the amount of previously accrued interest that has not been converted
reflected in the principal outstanding. Such replacement Note (resulting from the partial conversion) shall be delivered to the
Holder on or prior to the tenth (10th) day after the applicable Conversion Date.

 

7.       Adjustment
to Conversion Price. Except for any Exempt Issuance (as hereinafter defined), in the event the Corporation issues or sells
any securities including Options or Convertible Securities (or amends any outstanding securities of the Company), at an effective price
of, or with an exercise or conversion price of less than the Conversion Price, then upon such issuance or sale, the Conversion Price
shall be reduced to the sale price or the exercise or conversion price of the securities issued or sold. “Exempt Issuance”
shall mean any sale or issuance by the Corporation of its Common Stock or securities convertible into, exercisable for or exchangeable
for Common Stock in connection with (i) full or partial consideration in connection with a strategic merger, acquisition, consolidation
or purchase of the securities or assets of a corporation or other entity (or any division or business unit thereof), (ii) the Corporations
issuance of securities in connection with strategic supply, sale or license agreements and other partnering arrangements so long as such
issuances are not for the purpose of raising capital, (iii) the Corporation’s issuance of Common stock, restricted stock units
or the issuances or grants of Options to purchase Common Stock to employees, officers or directors, under an equity incentive plan adopted
by a majority of the non employee members of the Board of Directors of the Corporation; (iv) securities issued upon the exercise or exchange
of or conversion of any Convertible Securities issued and outstanding on the date of the issuance of Series E to securities holders of
the Corporation in exchange for other securities existing as of the date of this Note, (v) the conversion of any Series E, Series C-1
Convertible Preferred Stock and Series C-2 Convertible Preferred Stock or (vi) any equity line of credit or similar agreement, if
entered into with the consent of Doug Mergenthaler. In case any shares of Common Stock, Convertible Securities or Options are issued
in connection with the issue or sale of other securities of the Company, together comprising one integrated transaction, each share of
Common Stock underlying any such Convertible Securities or Options shall be deemed to be one additional share of Common Stock for the
purposes of determining the effective price of the non-Exempt Issuance.

 

    	-2-

    	 

    

 

8.       Adjustment
of Conversion Price upon Subdivision or Combination of Common Stock. If the Corporation at any time on or after the Issue
Date subdivides (by any stock split, stock dividend, recapitalization or other similar transaction) one or more classes of its
outstanding shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision
will be proportionately reduced. If the Corporation at any time on or after the Issue Date combines (by any reverse split, recapitalization
or other similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the
Conversion Price in effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to
this Section 8 shall become effective immediately after the effective date of such subdivision or combination.

 

9.       Acquisition.
Immediately prior to the closing of a merger, share exchange, consolidation, acquisition of all or substantially all of the
assets or stock, reorganization or liquidation of the Company that results in the stockholders of the Company immediately prior
to such transaction owning less than 50% of the voting capital stock of the Company (or its successor or parent corporation) immediately
after the transaction or, in the case of a sale of assets or liquidation, the Company owning after the transaction less than substantially
all of the assets owned by the Company prior to the transaction (other than an issuance of equity securities for the primary purpose
of raising capital) (an “Acquisition”) that occurs prior to the satisfaction in full by the Company
of all outstanding Principal Amount and accrued but unpaid interest under this Note (including through the conversion of such
amounts into capital stock of the Company), the Holder may elect to either (i) convert all outstanding Principal Amount and accrued
interest hereunder into shares of Common Stock at the valuation of the Company on a per share basis as used in the Acquisition,
or (ii) accelerate the Maturity Date to the date of closing of the Acquisition transaction and thereupon the Company shall be
obligated to pay Holder an amount equal to the remaining Conversion Amount in full satisfaction of its obligations hereunder.
In conjunction with such conversion in connection with an Acquisition, the Holder shall execute all documentation required to
be executed by other stockholders of Company in connection with the Acquisition (the “Acquisition Agreements”),
including without limitation escrow, indemnification and other similar agreements.

 

10.       Effect
of Conversion. Upon conversion of this Note into shares of the Company’s Common Stock in accordance with the terms hereof,
and, if and as applicable, upon receipt by the Company of signature pages to the Acquisition Agreements executed by the Holder,
the Company shall promptly issue and deliver to the Holder (a) certificates for the shares issuable upon such conversion of this
Note (“Conversion Shares”) and (b) a capitalization table that reflects the Company’s Fully-Diluted
Number of Shares as of the Conversion Time (as defined below) certified as accurate and complete by a senior officer of the Company
(if such information is not otherwise contained in the Acquisition Agreements). Such conversion shall be deemed to have been made,
in the case of conversion pursuant to Section 2, as of the close of business on the Maturity Date or such earlier date
as mutually agreeable to the Company and Holder; in the case of a listing on a Qualified National Exchange, simultaneously with
the completion of the initial listing and trading of the Common Stock on a Qualified National Exchange; and in the case of an
Acquisition, immediately prior to the closing of such Acquisition (in each case, the “Conversion Time”).
The Holder shall be treated for all purposes as the record holder of such Conversion Shares as of the Conversion Time. No fractional
Conversion Shares shall be issued in connection with any conversion of this Note, and any fractional share shall be rounded up
or down to the nearest whole share in lieu of any such fraction (and any fraction representing one-half of a share shall be rounded
up). The issuance of Conversion Shares to the Holder upon conversion of this Note in accordance with its terms shall constitute
satisfaction in full of the obligations of the Company under this Note.

 

    	-3-

    	 

    

 

11.       Event
of Default. If the Company (a) fails to pay when due any principal or interest payment on the due date hereunder, and such
payment shall not have been made within thirty (30) days of the Company’s receipt of the Holder’s written notice to
the Company of such failure to pay; (b) materially breaches any other covenant contained in this Note or the Purchase Agreement
and such failure continues for forty-five (45) days after the Company receives written notice of such material breach from the
Holder; (c) voluntarily files for bankruptcy protection or makes a general assignment for the benefit of creditors; or (d) is
the subject of an involuntary bankruptcy petition and such petition is not dismissed within ninety (90) days, then in any such
case then the holders of Notes owning together in excess of a majority of the aggregate Principal Amount of the Notes may, upon
written notice to the Company, declare the 2021 Notes (including this Note) in default and immediately due and payable in full.
From that date forward, this Note shall bear interest at a rate of the lower of ten percent (10%) per annum or the highest rate
allowed by applicable law, until paid in full or converted.

 

12.       Security
Agreements. This Note is secured by certain tangible assets of the Company pursuant to that certain Security Agreement (as
amended, restated or otherwise modified from time to time, the “Security Agreement”) dated as of the
Issue Date, between the Company and the Holder and each of the other parties thereto from time to time as specified in such Security
Agreement.

 

13.       Ranking.
This Note and the other 2021 Notes shall rank pari passu as to the payment of principal and interest. The Holder agrees that
any payments or prepayments to the Holder and to the holders of the other 2021 Notes, whether principal, interest or otherwise,
shall be made pro rata among the Holder and the other holders of the 2021 Notes based upon the aggregate unpaid principal amount
of this Note and the other 2021 Notes. Notwithstanding the foregoing, this Note shall rank senior to any unsecured debt of the
Company and to any other promissory notes issued by the company, provided that this Note shall rank pari passu to any other
2021 Note.

 

14.       Restrictions
on Transfer and IPO Lock-Up. As a condition to the conversion of this Note into equity securities of the Company, Holder understands
that the Conversion Shares are subject to restrictions on transfer under the Securities Act and applicable state securities laws
as well as other contractual restrictions that are in existence at the time of issuance of the Conversion Shares, including under
the Bylaws of the Company.

 

Holder
further understands and acknowledges that, notwithstanding anything to the contrary in this Note, the Note may not be converted
into shares of Common Stock and no Conversion Shares may be issued by the Company to Holder until the Company is current in its
reporting obligations with the SEC and upon the CUSIP eligibility of the Conversion Shares.

 

If
applicable, the Conversion Shares (unless registered under the Securities Act of 1933, as amended) will be stamped or imprinted
with a legend in substantially the following form:

 

THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.

 

    	-4-

    	 

    

 

15.       No
Rights as a Shareholder. Holder is not entitled, as a Holder in respect of this Note, to any rights as a shareholder of the
Company and Holder shall not be deemed the holder of the Conversion Shares or any other securities of the Company that may at
any time be issuable on the conversion of this Note for any purpose, nor will anything contained herein be construed to confer
upon the Holder, as such, any of the rights of a shareholder of the Company or any right to vote for the election of directors
or upon any matter submitted to shareholders at any meeting thereof, or to give or withhold consent to any corporate action (whether
upon any recapitalization, issuance of shares, reclassification of shares, change of par value, consolidation, merger, conveyance,
or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until this Note has
been converted and the Conversion Shares issuable upon the conversion hereof have been issued or become deliverable, as provided
herein.

 

16.       Subordination.
By accepting this Note, the Holder agrees that all payments on account of the indebtedness, liabilities and other obligations
of the Company to the Holder, including, without limitation, all amounts of principal, interest accrued hereon, and all other
amounts payable by the Company to the Holder under this Note or in connection herewith shall be subordinated and subject in right
of payment, to the extent and manner set forth herein, to the prior payment in full in cash or cash equivalents of any existing
or future Senior Indebtedness of the Company. “Senior Indebtedness” shall mean any (i) indebtedness,
liabilities and other obligations of the Company or with respect to which the Company is a guarantor, to banks, insurance companies
or other lending or thrift institutions regularly engaged in the business of lending money, whether or not secured, (ii) indebtedness,
liabilities and other obligations of the Company under any line of credit or revolving credit facility and (iii) any deferrals,
renewals or extensions or any debentures, notes or other evidence of indebtedness issued in exchange for such Senior Indebtedness.
Upon request from the Company, each Holder will agree to execute and deliver a subordination agreement, in a form reasonably acceptable
to any banks, insurance companies or other lending or thrift institutions holding Senior Indebtedness, subordinating the Holder’s
interests under this Note to the interests of any banks, insurance companies or other lending or thrift institutions holding Senior
Indebtedness.

 

Upon
any receivership, insolvency, assignment for the benefit of creditors, bankruptcy, reorganization, or arrangement which creditors
(whether or not pursuant to bankruptcy or other insolvency laws), sale of all or substantially all of the assets, dissolution,
liquidation, or any other marshaling of the assets and liabilities of the Company or in the event this Note shall be due and payable
(including upon maturity), (i) no amount shall be paid by the Company, whether in cash or property in respect of the principal
of or interest on this Note at the time outstanding, unless and until the full amount of any Senior Indebtedness then outstanding
shall be paid in full, and (ii) no claim or proof of claim shall be filed with the Company by or on behalf of the holder of this
Note which shall assert any right to receive any payments in respect of the principal of and interest on this Note except subject
to the payment in full all of the Senior Indebtedness then outstanding.

 

If
an event of default has occurred with respect to any Senior Indebtedness, permitting the holder thereof to accelerate the maturity
thereof, then unless and until such event of default shall have been cured or waived or shall have ceased to exist, or all Senior
Indebtedness shall have been paid in full, no payment shall be made in respect of the principal of or interest on this Note and
no action shall be taken to collect on any of the principal of or interest on this Note. For purposes of clarity, the conversion
of this Note into Conversion Shares or any other equity security of the Company shall not be deemed a payment for purposes of
this Section 9 and shall be expressly permitted without regard to the Senior Indebtedness.

 

    	-5-

    	 

    

 

17.       Notices.
All notices provided for in this Note shall be in writing and deemed to be duly given upon (a) delivery via electronic mail (provided
no notice of failure of delivery is received by the sender) or in person, (b) four business days after deposit in the United States
mail, certified or registered, postage prepaid and (c) one business day after deposit with a reputable, national overnight courier
service for next business day delivery with all charges prepaid. Notices shall be sent, with respect to the Company, to the address
set forth below, and with respect to Holder, to the address set forth on the signature page hereto or at such other address as
such party may designate by ten (10) days advance written notice to the other party given in the foregoing manner:

 

	 	If
    to Company:	Theralink
        Technologies, Inc.

        15000
        W. 6th Ave., #400

        Golden,
        CO 80401

        Attn:
        Mick Ruxin, CEO

        Email:
        mick@theralink.com
	 
	 	 	 	 
	 	With
    copy to:	K&L
        Gates LLP

        200
        S. Biscayne Blvd., Ste. 3900

        Miami,
        Florida 33131

        Attn:
        Clayton Parker, Esq.

        Email:
        clayton.parker@klgates.com
	 

 

18.       
Governing Law. This Note, and any disputes arising under this Note, will be governed by and construed in accordance with the
laws of the State of Nevada, without giving effect to any conflict of laws principle to the contrary. The Company and the Holder
agree that the state and federal courts located in Nevada will have exclusive jurisdiction over any dispute between them arising
out of this Note.

 

19.       
Assignment. The rights and obligations of the Company and the Holder shall be binding upon and shall inure to the benefit
of their successors, assigns and transferees. Holder may not assign or otherwise transfer this Note without the prior written
consent of the Company.

 

20.       Waiver
and Amendment. The provisions of this Note may be amended or waived only upon the written consent of the Company and the Holder.

 

21.       
Collection Costs. The Company agrees to pay all costs and expenses, including without limitation reasonable attorneys’
fees, incurred by the Holder in any action brought to enforce the terms of this Note and/or to collect this Note, and in any appeal
thereof.

 

22.       
Headings. Headings used in this Note have been included for convenience and ease of reference only, and will not in any manner
influence the construction or interpretation of any provision of this Note.

 

23.       Only
Company Liable. In no event shall any stockholder, officer, director or employee of the Company be liable for any amounts
due or payable pursuant to this Note.

 

24.       Expenses.
Each of the Company and the Holder will bear its own expenses associated with the negotiation and execution of this Note.

 

25.       Counterparts.
The Note may be executed in two counterparts, each of which will be deemed an original, but all of which together will constitute
one and the same instrument.

 

*
* * *

 

    	-6-

    	 

    

 

The
Company has caused this Convertible Secured Promissory Note to be signed by its duly authorized officer and dated the day and
year first above written.

 

THERALINK
TECHNOLOGIES, INC.

 

	By:	/s/
    Mick Ruxin	 
	Name:	Mick
    Ruxin	 
	Title:	Chief
    Executive Officer	 

 

AGREED
AND ACCEPTED:

 

Ashton
Capital Corporation

 

	By:
    	/s/
    Yvonne Fors	 
	Name:	Yvonne
    Fors	 
	Title:	VP
    of Finance	 

 

Address:
1201 Monster Road SW, Suite 350, Renton WA 98057

Email:
yvonnef@ashtoncorp.com

 

SIGNATURE
PAGE TO CONVERTIBLE SECURED PROMISSORY NOTE

 

    	 

    	 

    

 

EXHIBIT
A

NOTICE
OF CONVERSION

(To
be executed by the Holder in order to convert this Note)

 

To:
Theralink Technologies, Inc.15000 W. 6th Ave., #400

Golden,
CO 80401

Attn:
Chief Executive Officer

 

The
undersigned hereby irrevocably elects to convert $                
of the outstanding principal and/or accrued interest of the above Note into shares of Common Stock of Theralink Technologies,
Inc., according to the conditions stated therein, as of the Conversion Date written below.

 

Conversion
Date:

Applicable
Note Conversion Price:

Signature:

Name:

Address:

Amount
to be converted:            $

Amount
of Note unconverted:    $

Note
Conversion Price per share:

Number
of shares of Common Stock to be issued:

Please
issue the shares of Common Stock in the following name and to the following address:Exhibit
4.2

 

NEITHER
THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

COMMON
STOCK PURCHASE WARRANT

 

THERALINK
TECHNOLOGIES, inc.

 

	Warrant
    Shares: 63,897,764	 	Issue
    Date: May 12, 2021

 

THIS
COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, Ashton Capital Corporation
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time after the Issue Date and on or after the period that the Company (as defined below) is current in its reporting
obligations with the Securities and Exchange Commission and upon the CUSIP eligibility of the Warrant Shares (as defined below)
(the “Initial Exercise Date”) and on or prior to the close of business on the Termination Date (as defined
below) but not thereafter, to subscribe for and purchase from Theralink Technologies, Inc., a Nevada corporation (the “Company”),
of up to 63,897,764 shares (subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common
Stock, par value $0.0001 per share (“Common Stock”). This Warrant is being issued in connection with the Securities
Purchase Agreement, dated May 12, 2021 by and between the Company and the Holder pursuant to which the Holder is purchasing from
the Company a convertible secured promissory note.

 

Section
1. Exercise; Termination Date.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such
other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto
as Annex A; and, within three (3) Business Days of the date said Notice of Exercise is delivered to the Company, the Company
shall have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s
check drawn on a United States bank. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three
(3) Business Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise Form within two (2) Business Days of receipt of such notice. In the event
of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error.
The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof. As used herein, “Business Day”
means any day except Saturday, Sunday or any other day on which commercial banks located in the State of Nevada are authorized
or required by law to be closed for business.

 

    	1

    	 

    

 

b)
Exercise Price. The exercise price (the “Exercise Price”) of this Warrant shall be $0.00313 per Warrant
Share, subject to adjustment hereunder.

 

c)
Mechanics of Exercise.

 

i.
Delivery of Certificates Upon Exercise. Certificates for the Warrant Shares purchased or exercised hereunder shall be transmitted
by the Company’s transfer agent to the Holder by crediting the account of the Holder’s broker with the Depository
Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”) system if the Company is then a participant
in such system and there is an effective registration statement permitting the resale of the Warrant Shares and otherwise by physical
delivery to the address specified by the Holder in the Notice of Exercise within three (3) Business Days from the delivery to
the Company of the Notice of Exercise Form, surrender of this Warrant (if required), and payment of the aggregate Exercise Price
(unless cashless exercise is utilize) as set forth above (the “Warrant Share Delivery Date”). This Warrant
shall be deemed to have been exercised on the date the Exercise Price is received by the Company (or notice of cashless exercise
is received). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named
therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been
exercised by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to
Section 1(c)(v) prior to the issuance of such shares, have been paid.

   

  ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

   

  iii. Rescission Rights. If the Company fails to cause the Company’s transfer agent to transmit to the Holder a certificate or the certificates representing the Warrant Shares pursuant to Section 1(c)(i) by the Warrant Share Delivery Date, then, the Holder will have the right to rescind such exercise.

   

  iv. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

   

  v. Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder, and such other documentation as the Company may require regarding the investor status of the assignee, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

   

  vi. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

 

    	2

    	 

    

 

d)
Termination Date. This Warrant shall be exercisable from the Initial Exercise Date until May 12, 2026 (the “Termination
Date”).

 

Section
2. Certain Adjustments.

 

a)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, (v) the Company, directly or indirectly, in one
or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another person or group of persons whereby
such other person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other person or other persons making or party to, or associated or affiliated with the other persons making
or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the
Holder, the number, class, and series of shares of stock of the successor or acquiring corporation or of the Company, if it is
the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a
result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price
shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of
this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction
in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations
of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 2(a)
pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without
unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance
to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent
entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any
limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock
and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence
of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the
date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity
had been named as the Company herein.

 

    	3

    	 

    

 

b) Equity Issuances.
Except for any Exempt Issuance (as hereinafter defined), in the event the Company issues or sells any securities including options or
convertible securities (or amends any outstanding securities of the Company), at an effective price of, or with an exercise or conversion
price of less than the Exercise Price, then upon such issuance or sale, the Exercise Price shall be reduced to the sale price or the
exercise or conversion price of the securities issued or sold. “Exempt Issuance” shall mean any sale or issuance by the Company
of its Common Stock or securities convertible into, exercisable for or exchangeable for Common Stock in connection with (i) full or partial
consideration in connection with a strategic merger, acquisition, consolidation or purchase of the securities or assets of a corporation
or other entity (or any division or business unit thereof), (ii) the Company’s issuance of securities in connection with strategic
supply, sale or license agreements and other partnering arrangements so long as such issuances are not for the purpose of raising capital,
(iii) the Company’s issuance of Common Stock, restricted stock units or the issuances or grants of options to purchase Common Stock
to employees, officers or directors, under an equity incentive plan adopted by a majority of the non employee members of the Board of
Directors of the Company; (iv) securities issued upon the exercise or exchange of or conversion of any convertible securities issued
and outstanding on the date of the issuance of Series E to securities holders of the Company in exchange for other securities existing
as of the date of this Warrant, (v) the conversion of any Series E, Series C-1 Convertible Preferred Stock and Series C-2 Convertible
Preferred Stock or (vi) any equity line of credit or similar agreement, if entered into with the consent of Doug Mergenthaler. In case
any shares of Common Stock, convertible securities or options are issued in connection with the issue or sale of other securities of
the Company, together comprising one integrated transaction, each share of Common Stock underlying any such convertible securities or
options shall be deemed to be one additional share of Common Stock for the purposes of determining the effective price of the non-Exempt
Issuance.

 

c)
Stock Dividends and Splits. If the Company, at any time while
this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock
or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include
any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into
a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller
number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in
each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common
Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately
adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged, subject to the limitation on fractional shares
in Section 2(d)(iv). Any adjustment made pursuant to this Section 2(b) shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.

 

d)
Calculations. All calculations under this Section 2 shall
be made to the nearest cent or the nearest 1/100th of a share, as the case may be.

 

e)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2,
the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and setting forth a brief statement of the facts requiring such adjustment.

   

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered
by facsimile or email to the Holder at its last facsimile number of email address as it shall appear upon the Warrant Register
of the Company, at least five (5) calendar days prior to the applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure
to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. The Holder is entitled to exercise this Warrant during the period commencing on the date
of such notice to the effective date of the event triggering such notice.

 

    	4

    	 

    

 

Section
3. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the reasonable conditions and documentation
required by the Company, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with
a written assignment of this Warrant substantially in the form attached hereto as Annex B (the “Assignment Form”),
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of
such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. The Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued.

 

b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 3(a), as to any transfer which may be
involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the
Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall
be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.

 

c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section
4. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1(a).

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve, from its
authorized and unissued Common Stock, a sufficient number of shares to provide for the issuance of the Warrant Shares upon the
exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute
full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary
certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of
any applicable law or regulation, or of any requirements of the business market upon which the Common Stock may be listed. The
Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant
will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect
of any transfer occurring contemporaneously with such issue).

 

    	5

    	 

    

 

e)
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined by applying the laws of the State of Nevada, without regard to its conflicts of laws provisions.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant will have restrictions
upon resale imposed by state and federal securities laws unless (i) such Warrant Shares are registered; or (ii) the resale of
the Warrant Shares satisfies an exemption from registration under the Securities Act.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the
fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any
of its rights, powers or remedies hereunder.

 

h)
Notices. All notices and other communications from the Company to the Holder of this Warrant shall be sent by electronic
transmission or overnight courier or shall be mailed by first class registered or certified mail, postage prepaid, at such address
as may have been furnished to the Company in writing by such Holder. All such notices and communications shall, when mailed, be
effective when deposited in the mails and, when sent by electronic transmission or overnight courier, delivered, be effective
when received.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

 

j)
Successors and Assigns. Subject to applicable federal and state securities laws, this Warrant and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this
Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

k)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.

 

l)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

m)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	6

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	THERALINK
    TECHNOLOGIES, INC.
	 	 
	 	By	/s/
Mick Ruxin
	 	Name:	Mick
    Ruxin
	 	Title:	Chief
    Executive Officer

 

    	 

    	 

    

 

ANNEX
A

 

NOTICE
OF EXERCISE

 

 

To:
THERALINK TECHNOLOGIES, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and

 

 

(2)
Payment shall take the form of lawful money of the United States:

 

(3)
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name
as is specified below:

 

_______________________________

 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)
Accredited Investor. The undersigned is an “accredited investor” as defined in Rule 501(a) of Regulation D,
promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

	Name
    of Investing Entity: ___________________________________________________________________________
	 
	Signature
    of Authorized Signatory of Investing Entity: _____________________________________________________
	 
	Name
    of Authorized Signatory: _______________________________________________________________________
	 
	Title
    of Authorized Signatory: ________________________________________________________________________
	 
	Date:
    ___________________________________________________________________________________________

 

    	 

    	 

    

 

ANNEX
B

 

ASSIGNMENT
FORM

 

	(To
    assign the foregoing warrant, execute
	this
    form and supply required information.
	Do
    not use this form to exercise the Warrant.)

 

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

_______________________________________________
whose address is

 

_______________________________________________________________.

 

_______________________________________________________________

 

	 	Dated:	______________, ___________

	 	 	 
	 	Holder’s Signature:	_______________________________
	 	 	 
	 	Holder’s Address:	_______________________________
	 	 	 
	 	 	_______________________________

 

Signature
Guaranteed: ___________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those
acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]